Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Ilaris Approved For Rare Autoinflammatory Disorder; Filings For More Common Diseases Planned

This article was originally published in The Pink Sheet Daily

Executive Summary

Development portfolio for interleukin-1ß blocker is sign of success for Novartis proof of concept R&D development model.

You may also be interested in...



CANTOS Trial Brings Unexpected CVD Promise For Novartis & Regeneron

Few expected the positive top-line results from CANTOS showing the Phase III cardiovascular disease study using canakinumab met the primary endpoint. Most want to see the full details being unveiled later in 2017.

IL-17: Pushing The Limits Of A Drug Target

A series of recent and anticipated events is drawing attention to interleukin-17 and related cytokines – a set of immunological drug targets of long-standing interest to large and small companies. The current crop of big-company candidates are biologics and may prove too harsh for all but the most severe immunological conditions, leaving room for start-ups developing small molecules.

Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter

The agency seeks more clinical data on canakinumab in refractory patients after an advisory committee meeting that focused on the drug's potential risks.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069574

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel